International Journal of Biological Macromolecules, Год журнала: 2024, Номер 283, С. 137133 - 137133
Опубликована: Ноя. 12, 2024
Язык: Английский
International Journal of Biological Macromolecules, Год журнала: 2024, Номер 283, С. 137133 - 137133
Опубликована: Ноя. 12, 2024
Язык: Английский
Annals of Intensive Care, Год журнала: 2024, Номер 14(1)
Опубликована: Апрель 2, 2024
Abstract Background Legionnaires’ disease (LD) is a common but under-diagnosed cause of community-acquired pneumonia (CAP), although rapid detection urine antigen testing (UAT) and advances in molecular have improved the diagnosis. LD entails intensive care unit (ICU) admission almost one-third cases, mortality rate ranges from 4% to 40%. This review aims discuss recent study this condition provide an update on diagnosis, pathogenesis management severe LD. Results The overall incidence has increased worldwide years due higher number patients with risk factors, especially immunosuppression, improvements diagnostic methods. Although responsible for only around 5% all-cause CAP, it one three most causes CAP requiring ICU admission. Mortality patients, immunocompromised or nosocomial source can reach 40% despite appropriate antimicrobial therapy. Regarding pathogenesis, no Legionella -specific virulence factors been associated severity; however, reports found high pulmonary DNA loads, impairments immune response lung microbiome cases. clinical picture includes injury respiratory and/or hemodynamic support, extrapulmonary symptoms non-specific laboratory findings. methods broad use UAT development allowing all Lp serogroups. Therapy currently based macrolides, quinolones, combination two, prolonged treatment Conclusions Numerous influence LD, such as admission, underlying status, infection. host (hyperinflammation immunoparalysis) may also be severity. Given that rising, studies specific biomarkers severity great interest. Further assessments comparing different regimens evaluating host-directed therapies are nowadays needed. Graphical
Язык: Английский
Процитировано
12Aquaculture, Год журнала: 2024, Номер 585, С. 740724 - 740724
Опубликована: Фев. 27, 2024
Язык: Английский
Процитировано
10Nature Communications, Год журнала: 2024, Номер 15(1)
Опубликована: Сен. 27, 2024
Язык: Английский
Процитировано
4Chinese Science Bulletin (Chinese Version), Год журнала: 2025, Номер 70(10), С. 1446 - 1459
Опубликована: Янв. 22, 2025
Язык: Английский
Процитировано
0Microbial Biotechnology, Год журнала: 2025, Номер 18(5)
Опубликована: Апрель 28, 2025
ABSTRACT The respiratory tract microbiome (RTM) is a multi‐kingdom microbial ecosystem that inhabits various niches of the system. While previously overlooked, there now sufficient evidence RTM plays crucial role in human health related to immune system training and protection against pathogens. Accordingly, dysbiosis or disequilibrium has been linked several communicable non‐communicable diseases, highlighting need unveil its disease. Here, we define place medicine. Moreover, outline challenges research, emphasising for combining methodologies, including multi‐omics computational tools. We also discuss RTM's potential diagnosing, preventing treating diseases developing novel microbiome‐based therapies improve pulmonary health.
Язык: Английский
Процитировано
0Pathogens, Год журнала: 2025, Номер 14(4), С. 355 - 355
Опубликована: Апрель 5, 2025
Antibiotic resistance represents a growing public health threat, with airborne drug-resistant strains being especially alarming due to their ease of transmission and association severe respiratory infections. The microbiome plays pivotal role in maintaining health, influencing the dynamics antibiotic among pathogenic microorganisms. In this context, review proposes exploration complex interplay between microbiota antimicrobial resistance, highlighting implications diversity disease. Moreover, strategies mitigate including stewardship programs, alternatives traditional antibiotics, probiotics, restoration techniques, nanotechnology-based therapeutic interventions, are critically presented, setting an updated framework current management options. Therefore, through better understanding roles alongside emerging strategies, paper aims shed light on how global challenges posed by multi-drug-resistant pathogens can be addressed.
Язык: Английский
Процитировано
0Pneumonia, Год журнала: 2025, Номер 17(1)
Опубликована: Май 4, 2025
To ascertain the role of lung microbiome in development severe pneumonia and its potential as a biomarker for disease progression. BAL samples from 34 adults with community-acquired (CAP) (17 viral, 8 viral coinfected bacteria 9 bacterial) admitted to ICU acute respiratory failure between 2019 2021 were collected within first 48 h admission ICU. The was characterized via Ion 16S Metagenomics Kit Torrent sequencing platform. Clinical factors, including survival, mechanical ventilation duration, blood biomarkers organ terms distress syndrome (ARDS), shock or renal failure, correlated characteristics. diversity patients significantly greater than that bacterial pneumonia: Shannon index 3.75 (Q1-Q3: 2.5-4.1) versus 0.4 0.2-1.3) 0.48 0.3-1.1), respectively (p < 0.05). associated severity-of-illness (APACHE II), independent etiology (B coefficient -1.845; p 0.01). Patients CAP who developed ARDS had lower presence Proteobacteria, those complicated ventilator-associated higher prevalence Acinetobacter at admission. mortality 35%. In patients, shock. have low diversity, indicating is severity.
Язык: Английский
Процитировано
0Annals of Clinical Microbiology and Antimicrobials, Год журнала: 2023, Номер 22(1)
Опубликована: Ноя. 29, 2023
Legionnaires' Disease (LD) rarely evolves into pulmonary abscesses. The current systematic review has been designed to explore therapeutical strategies in cavitary LD.A research strategy was developed and applied the databases Embase, Pubmed, Web of Science from 1st January 2000 November 2022. Original articles, case series, reports, guidelines written English, French, German, Italian, Dutch were considered. Furthermore, medical records patients treated at University Hospital UZ Brussel for LD pneumonia, between 2016 2022, reviewed.Two found by Brussel's investigation. Through literature review, 23 reports describing 29 patients, seven identified. overall evidence level low.The median age 48 years 65% male. A polymicrobial infection detected 11 (44%) with other aerobic bacteria being most commonly found. At diagnosis, 52% received combination therapy, fluoroquinolones preferred antimicrobial class. Anaerobic coverage neglected 33% patients.Three favor monotherapy or macrolides, while one suggested an severe LD. Four recommended anaerobic lung abscesses.To date, supporting treatment is low. Monotherapy lowers toxicity might be as effective therapy. Finally, anaerobes should not neglected.
Язык: Английский
Процитировано
4Scientific Reports, Год журнала: 2024, Номер 14(1)
Опубликована: Сен. 30, 2024
Язык: Английский
Процитировано
0International Journal of Biological Macromolecules, Год журнала: 2024, Номер 283, С. 137133 - 137133
Опубликована: Ноя. 12, 2024
Язык: Английский
Процитировано
0